secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096799
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron reports Q3 2024 revenue up 177% YoY to $1.8M; HLHS trial enrollment >80%
--------------------------------------------------------------------------------

- Revenue for nine months ended Sept 30, 2024: $1.8M, up 177% YoY from $0.6M.
- Net loss narrowed to $11.9M for nine months 2024 from $15.3M in 2023, a 23% improvement.
- Cash and equivalents $22.8M; expects to fund operations through Q4 2025.
- Phase 2b HLHS trial ELPIS II >80% enrolled; FDA confirmed pivotal trial acceptable for BLA if positive.
- Phase 2a Alzheimer's data (CLEAR MIND) presented at AAIC and CTAD24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/0001213900-24-096799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/ea0220665-8k_longe.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer